Job Cuts As Polyphor Focuses On First-In-Class Anticancer
And Cystic Fibrosis Antibiotic
Switzerland’s Polyphor has redefined its business strategy and is aiming to become a leaner organization, with a potential first-in-class immuno-oncologic, balixafortide, in late-stage clinical development for breast cancer.
